During OA therapy, the FII:C seems useless as a diagnostic tool. FX:C was not significantly lower among the carriers [140 (95% CI, 110 -170) units/L vs 170 (95% CI, 150 -180) units/L; P ϭ 0.31], but the ratio was higher [2.54 (95% CI, 2.26 -2.82)] than in non-carriers [2. 01 (95% CI, 1.92-2.10); P Ͻ0.0001]. The sensitivity was 0.82, and the specificity was 0.58 for a cutoff of 2.1. A good negative predictive value of 0.95 corresponded to an unacceptable positive predictive value (0.25; see Table  1 ). The 2.40 cutoff showed the best likelihood ratio of a positive result (3.1) but correctly classified only 77% of the patients. The nonparametric estimation for the area under the ROC curve was 0.73 (9 ).
In summary, although a non-anticoagulated population should be evaluated to obtain definitive conclusions, many thromboembolic patients are referred to the outpatient clinic for investigation while being treated with OA, and many recurrent cases may require lifelong treatment.
During stable OA therapy, FX activity could be a good marker of FII oscillations. In these subjects, the FII:C/FX:C ratio was significantly higher when the mutation FII 20210A existed (2.54 vs 2.01; P Ͻ0.0001), but disappointing results were obtained when we attempted to use it for a diagnostic purpose. 
).
We have examined the possible antiandrogenic activity of genistein using the steroid hormone receptorpositive breast cancer cell line BT-474. This cell line, when stimulated by dihydrotestosterone (DHT), produces prostate-specific antigen (PSA), which is then secreted into the tissue culture supernatant and can be measured quantitatively by immunoassay. Details of this system are given elsewhere (5 ) . To study the antiandrogenic activity, the cells were first exposed to the putative antiandrogen (10 Ϫ5 to 10 Ϫ8 mol/L) for 1 h and then stimulated with DHT (10 Ϫ9 mol/L). Controls with only antiandrogen or only DHT were included in all experiments. Nilutamide was used as a control antiandrogen. Our data (Fig. 1) clearly demonstrate the potent antiandrogenic activity of genistein, which is dosedependent and is detectable down to 10 Ϫ7 mol/L. Quercetin and several other flavonoids tested were devoid of such activity (data not shown).
These data clearly demonstrate for the first time that genistein exhibits potent antiandrogenic activity in addition to its well-established estrogenic activity. Indeed, the therapeutic potential of this compound in prostate cancer patients may be related to its combined estrogenic and antiandrogenic properties. It will be interesting to examine large numbers of natural compounds for antiandrogenic activity, which may qualify them as candidate therapeutic and preventive agents for prostate, breast, and possibly other hormonally dependent cancers. BT-474 human breast cancer cells were grown to confluency in phenol-free RPMI (Life Technologies) supplemented with 100 mL/L fetal calf serum, 10 g/L insulin, and 200 mmol/L L-glutamine at 37°C in 5% CO 2 . Once confluent, they were subcultured in 24-well microtiter plates using the same medium but with substitution of charcoal-stripped fetal calf serum for the regular fetal calf serum. The cells were stimulated with candidate blocker [genistein (ࡗ), quercetin (u), or nilutamide (‚)], blocker and steroid (DHT), or steroid alone. Blockers were tested at concentrations of 10 Ϫ5 to 10 Ϫ8 mol/L, and DHT was used at 10 Ϫ9 mol/L. For the cells stimulated with blocker and steroid, the blocker was added first and incubated for 1 h; the cells were then stimulated with steroid. Alcohol was used as a negative control. The plates were then incubated for 7 days, at which time the tissue supernatants were harvested. The supernatants were then analyzed quantitatively for PSA. Blocking activity was assessed by dividing the amount of PSA produced by the candidate blocker ϩ steroid and by steroid alone and multiplying by 100. None of the candidate blockers induced any PSA production when added alone.
Rachel S. Rosenberg Zand

